14Sep/22

ADC Panoramic Overview-Linker

September 14, 2022ReviewADC linkerbioadc

The linker is not only the molecular part of the covalent connection between the antibody and the small molecular payload but also a key element with design properties in targeted drug therapy.Read More…

31Jul/22

About ADCs Payloads: Innovative Drug

July 31, 2022ReviewADCs Payloads, Amatoxin, Non-cleavable Linkers, Thailanstatin Abioadc

Innovative Drugs Apoptosis inducer (Bcl-xL inhibitor) The overexpression of anti-apoptotic Bcl-2 family members (including Bcl-xL) is one of the mechanisms by which cancer cells acquire apoptosis resistance. Drugs that block the BH3-bindingRead More…

31Jul/22

About ADCs Payloads: DNA-damaging Drug

July 31, 2022ReviewADCs Payloads, Calicheamicins, DNA-damaging Drugs, Duocarmycinbioadc

DNA-damaging Drugs Pyrrolobenzodiazepine and Indolinobenzodiazepine Pyrrolobenzodiazepines (PBD) is a kind of natural product with antineoplastic activity. Their mode of action is selective alkylation in a small groove of DNA, in which guanineRead More…

31Jul/22

About ADCs Payloads: Microtubule-destroying Drug

July 31, 2022ReviewADCs Payloads, Auristatin F, DM4, Microtubule-destroying drugsbioadc

Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…

22Apr/22

The Review of New Drug Conjugates

April 22, 2022ReviewABC, ADC, AECbioadc

With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…

24Nov/21

Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)

November 24, 2021ReviewADC Therapy, CEACAM5, DM4, Phase III ADCsbioadc

An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…

08Jul/21

Analytical methods of average drug to antibody ratio (DAR) of antibody-drug conjugates

July 8, 2021ReviewADCs, DAR analysis, HIC, HILIC, LC-MS, Ultraviolet spectrophotometrybioadc

Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…

30Apr/21

How To Design Elite ADCs?

April 30, 2021ReviewADC designbioadc

After more than 20 years of development, ADC drug is becoming the main force in cancer treatment, which, compared with traditional chemotherapy, has a wider application scope. However, minimizing ADCs’ non-target toxicityRead More…

29Mar/21

Comprehensively Review Targets for ADC

March 29, 2021ReviewADC targets, CD19, CD30, CD37, Trop2bioadc

At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…

30Nov/20

Analysis of the ADCs Drugs Approved by FDA

November 30, 2020ReviewADC, CD30, FDA ADCsbioadc

Antibody-drug conjugate (ADC) has achieved great progress in the past decade. So far, ten ADC drugs have been approved by the FDA, of which five were approved in 2019 and 2020, andRead More…